XML 93 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1
License, Acquisitions and Other Agreements (Tables)
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of milestone payments Amounts recorded to research and development expense for the period were as follows:
 Year Ended December 31,
 202420232022
Milestone Payments
$1,875 $3,250 $75 
Upfront Payments - Cash
6,000 — — 
Upfront Payments - Issuance of Common Shares*
$8,554 $— $— 
*The 2024 amount represents $8,554 recorded to research and development expense related to shares owed for upfront payments which were not yet issued as of December 31, 2024 and is recorded within accrued expenses and additional paid in capital on the consolidated balance sheet as of December 31, 2024.